Natalia V. Malkova
0009-0002-4519-0672
Publication & Citation Trends
Publications
0 total
Abstract 572: Tumor-activated PD1-directed IL-2 increased antigen specific T cells in tumors and demonstrated anti-tumor activity in mice
Cited by 1
Semantic Scholar
Abstract 587: A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models
Cited by 0
Semantic Scholar
719 XTX301, a protein-engineered IL-12, exhibits tumor-selective activity in mice without peripheral toxicities and is well tolerated in non-human primates OA
Cited by 2
Semantic Scholar
An experimental model of anti-PD-1 resistance exhibits activation of TGFß and Notch pathways and is sensitive to local mRNA immunotherapy OA
Cited by 25
Semantic Scholar
Abstract 3452: Pre-clinical development of next generation selective estrogen receptor degrader - SAR439859
Cited by 0
Semantic Scholar
Abstract 174: Genomic cytometry characterization of preclinical models for development of immune-oncology therapeutics
Cited by 0
Semantic Scholar
Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models
Cited by 2
Semantic Scholar
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade OA
Cited by 42
Semantic Scholar
Research Topics
Cytokine Signaling Pathways and Interactions
(44)
Cancer Immunotherapy and Biomarkers
(11)
CAR-T cell therapy research
(10)
Immunotherapy and Immune Responses
(9)
Monoclonal and Polyclonal Antibodies Research
(8)
Affiliations
California Institute of Technology
Sanofi (France)
AVEO Oncology (United States)
Development Agency of Serbia
Institute of Bioorganic Chemistry